AI-generated content for informational purposes only. Not financial advice. Always do your own research.

Zoetis
4.1 1 vote

Zoetis

Visit

About

World's largest animal health company, producing medicines, vaccines, and diagnostics for pets and livestock. Spun off from Pfizer in 2013.

Aging Population Stocks

Zoetis benefits from aging pet populations requiring more veterinary care as the world's leading animal health company, with a growing portfolio of diagnostics, medicines, and vaccines.

Pet Industry Stocks

Zoetis is the world's largest animal health company, producing medicines, vaccines, and diagnostics for pets and livestock, benefiting from the humanization of pet care and growing veterinary spending.

Key Financials ZTS

Price $126.65
Change (1D) +0.80%
Change (30D) +0.66%
Change (60D) +6.61%
Change (90D) -12.87%
Change (180D) -23.43%
Change (1Y) -27.16%
Change (5Y) -20.76%
P/E Ratio 34.05
EPS (TTM) $3.72
52-Week Range $115.25 — $177.00
50-Day MA $124.15
Volume 4.50M

Data updated Feb 15 · Source: Twelve Data

4.1 1 vote

AI Reviews

🤖
Claude Opus 4.6 Anthropic
4.1 /5

Zoetis is the global leader in animal health, commanding dominant market share in both companion animal and livestock pharmaceuticals and vaccines. The company benefits from powerful secular tailwinds: rising pet ownership, increasing pet humanization driving higher veterinary spending, and growing global protein demand. Its diversified portfolio spanning parasiticides, vaccines, dermatology (Apoquel/Cytopoint), and diagnostics provides resilient revenue streams.

However, the stock has faced significant headwinds, declining 27% over the past year and trading well below its 52-week high of $177. At a P/E of 34x on $3.72 EPS, the valuation remains elevated despite the pullback, suggesting the market still prices in premium growth. Concerns around GLP-1 drug impacts on pet obesity treatments, potential generic competition, and macroeconomic pressures on discretionary pet spending have weighed on sentiment.

The bull case rests on Zoetis's wide economic moat, consistent innovation pipeline, and the non-cyclical nature of essential veterinary care. The aging population connection is indirect but relevant"older demographics increasingly rely on companion animals, driving veterinary spending. For patient long-term investors, the pullback may present an attractive entry point into a best-in-class franchise, though near-term volatility could persist.

Category Ratings

Aging Population Stocks
3.6
Pet Industry Stocks
4.5
Feb 15, 2026
AI-Generated Review Generated via Anthropic API. This is an automated evaluation, not a consumer review. Learn more
Zoetis Screenshot

Added: Feb 15, 2026

zoetis.com

Categories

Aging Population Stocks Pet Industry Stocks